chronic
kidney
diseas
ckd
becom
global
healthcar
issu
ckd
progress
irrevers
endstag
renal
diseas
esrd
renal
failur
e
major
risk
factor
ckd
includ
obes
diabet
cardiovascular
diseas
understand
key
process
involv
diseas
develop
may
lead
novel
intervent
strategi
current
lag
behind
peroxisom
proliferatoractiv
receptor
c
pparc
one
ligandactiv
transcript
factor
superfamili
member
global
express
human
tissu
agonist
thiazolidinedion
tzd
appli
effect
antidiabet
drug
control
insulin
sensit
multipl
metabol
tissu
besid
tzd
exert
protect
effect
multipl
ckd
risk
diseas
context
pparc
abundantli
express
major
kidney
cell
physiolog
role
cell
studi
cell
anim
model
e
function
pparc
kidney
rang
energi
metabol
cell
prolifer
inflammatori
suppress
although
major
renal
side
effect
exist
agonist
includ
tzd
report
limit
applic
treat
ckd
current
review
system
assess
function
pparc
ckd
benefit
current
limit
agonist
clinic
applic
chronic
kidney
diseas
ckd
becom
one
common
diseas
world
chronic
renal
failur
end
stage
progress
variou
type
ckd
europ
unit
state
number
patient
endstag
renal
diseas
esrd
rapidli
increas
rate
per
year
esrd
patholog
character
renal
fibrosi
includ
glomerular
sclerosi
renal
interstiti
fibrosi
renal
fibrosi
almost
result
progress
kidney
diseas
complex
common
chronic
process
involv
multipl
mechan
extracellular
matrix
ecm
cytokin
secret
energi
metabol
podocyt
injuri
cell
prolifer
differenti
endoplasm
reticulum
stress
autophagi
infiltr
inflammatori
cell
activ
fibroblast
peroxisom
proliferatoractiv
receptor
ppar
ligandactiv
transcript
factor
tf
nuclear
hormon
receptor
superfamili
ree
ppar
subtyp
ppar
pparc
found
differ
speci
human
pparc
gene
locat
chromosom
contain
exon
expand
kb
gener
pparc
variant
ese
isoform
express
differ
differ
tissu
ppar
famili
protein
share
structur
similar
contain
cterminu
ligandbind
domain
respond
ligand
stimul
control
heterodimer
retinoid
x
receptor
rxr
upon
activ
ligand
stimul
lead
posttransl
modif
pparc
mapk
pathway
follow
conform
chang
proactiv
form
e
nterminu
dnabind
domain
recogn
bind
specif
respons
element
modul
gene
transcript
addit
regulatori
mechan
involv
coregul
complex
recruit
releas
dynam
control
ppar
activ
chromatin
level
pparc
interact
multipl
publish
coregul
energi
metabol
includ
coactiv
steroid
receptor
coactiv
pparc
coactiv
receptor
interact
protein
pr
domain
contain
well
corepressor
nuclear
receptor
corepressor
addit
pparc
repress
inflammatori
tf
activ
process
refer
transrepress
exampl
pparc
agonist
inhibit
nfkb
activ
mediat
inflammatori
respons
multipl
tissu
tf
report
coregul
pparc
includ
ccaatenhanc
bind
protein
c
ebp
famili
srebp
reverba
due
widespectrum
regulatori
effect
mutat
pparc
identifi
human
led
dysfunct
lipid
glucos
metabol
insulin
resist
develop
obesityinduc
dyslipidemia
nafld
cancer
pparc
abundantli
express
medullari
collect
duct
paraurethr
bladder
epitheli
cell
also
express
podocyt
mesangi
cell
vascular
endotheli
cell
although
fulli
delin
accumul
studi
suggest
pparc
play
import
role
regul
physiolog
function
kidney
current
studi
use
pparc
null
mice
agonist
conclud
tabl
e
antifibrot
role
pparc
well
accept
figur
treatment
mice
synthet
pparc
ligand
shown
attenu
experiment
induc
hepat
cardiac
kidney
fibrosi
e
antifibrot
renoprotect
effect
pparc
agonist
pioglitazon
troglitazon
also
confirm
type
diabet
rat
model
unilater
ureter
obstruct
uuo
mice
model
respect
multipl
mechan
potenti
involv
renoprotect
effect
pparc
activ
first
pparc
inhibit
cell
prolifer
apoptosi
report
pparc
agonist
pioglitazon
inhibit
mesangi
cell
prolifer
reduc
proteinuria
downregul
bcell
lymphoma
express
mitogenactiv
protein
kinas
mapk
phosphoryl
confirm
separ
studi
use
anoth
pparc
agonist
ciglitazon
e
vitro
treatment
ciglitazon
inhibit
prolifer
mous
mesangi
cell
induc
plateletderiv
growth
factor
pdgf
directli
affect
mapk
pathway
link
downregul
cyclin
exert
antiglomerular
sclerosi
effect
pretreat
rosiglitazon
significantli
inhibit
mesangi
cell
hypertrophi
prolifer
diabet
rat
e
effect
thiazolidinedion
tzd
puromycin
aminonucleosid
nephrosi
pan
increas
express
inhibit
necrosi
apoptosi
may
relat
upregul
bclxl
express
inhibit
activ
decreas
tgfbeta
pparc
agonist
inhibit
apoptosi
endotheli
cell
induc
tumor
necrosi
factor
tnf
also
inhibit
spontan
apoptosi
endotheli
cell
reduc
damag
glomerular
capillari
endothelium
inflamm
one
major
caus
kidney
injuri
declin
kidney
function
inflammatori
marker
creactiv
protein
inflammatori
cytokin
correl
end
stage
kidney
diseas
activ
pparc
allevi
inflamm
differ
type
kidney
cell
synthes
pparc
ligand
report
inhibit
chemokin
induc
inhibit
signal
pathway
mesangi
cell
rosiglitazon
activ
pparc
sumoyl
inhibit
ncor
degrad
activ
lpsstimul
renal
proxim
tubular
cell
turn
decreas
express
pparc
agonist
rosiglitazon
troglitazon
thiazolidinedion
attenu
excess
inflammatori
respons
activ
proxim
tubular
epitheli
cell
igan
suppress
express
loss
pparc
abund
transcript
activ
observ
glomerular
podocyt
experiment
rpgn
blunt
express
pparc
podocyt
nuclei
also
found
kidney
patient
diagnos
crescent
gn
ird
pparc
repress
transform
growth
pathway
signal
pathway
play
import
role
kidney
fibrosi
studi
shown
rosiglitazon
effect
block
fibrot
respons
elicit
explant
fibroblast
attenu
bleomycininduc
skin
fibrosi
vivo
subsequ
studi
varieti
cell
type
model
system
confirm
expand
find
pparc
activ
inhibit
plasminogen
activatinginhibit
human
mesangi
cell
e
express
extracellular
matrix
reduc
mechan
may
partli
posit
regul
pparc
hepatocyt
growth
factor
hgf
caus
increas
endogen
hgf
therebi
inhibit
pathway
pparc
agonist
troglitazon
ciglitazon
inhibit
signal
pathway
allevi
renal
fibroblast
activ
result
decreas
express
connect
tissu
growth
factor
ctgf
extracellular
matrix
synthesi
contribut
reduc
renal
fibrosi
progress
besid
pparc
influenc
epigenet
modif
kidney
diseas
induc
mesangi
cell
podocyt
injuri
pparc
diabet
nephropathi
dn
mediat
pparc
renal
calcium
oxal
crystal
format
lncrna
could
modul
ecm
accumul
dn
regul
target
pparc
howev
role
epigenet
modif
pparc
function
kidney
diseas
still
need
explor
import
regul
system
glucos
homeostasi
pparc
activ
improv
peripher
insulin
sensit
partli
increas
benefici
adipokin
ie
adiponectin
resistin
leptin
myokin
reduc
inflammatori
cytokin
intern
journal
nephrolog
zhou
et
al
system
pparc
delet
wholebodi
pparc
knockout
mice
e
null
mice
develop
sever
polydipsia
polyuria
reduc
urin
osmol
modest
hyperphagia
progress
weight
loss
h
water
depriv
null
mice
lower
urin
osmol
higher
urin
volum
greater
weight
loss
greater
rise
hematocrit
respons
urin
osmol
acut
chronic
vasopressin
treatment
attenu
adipos
tissu
muscl
also
induc
express
key
gene
involv
glucosestimul
insulin
secret
pancreat
beta
cell
besid
glucos
filtrat
reabsorpt
gluconeogenesi
kidney
regul
pparc
essenti
glucos
metabol
recent
studi
show
pparc
agonist
rosiglitazon
induc
hypoglycem
effect
inhibit
gluconeogenesi
proxim
tubul
cell
e
transport
glucos
kidney
depend
sodiumdepend
glucos
cotransport
sglt
local
epitheli
cell
proxim
renal
tubul
glucos
transport
glut
local
basolater
membran
wellcharacter
cotransport
sglt
famili
primarili
found
renal
tissu
glucos
filter
glomeruli
absorb
mutat
gene
associ
elev
urin
glucos
suggest
key
factor
glucos
reabsorpt
kidney
inhibit
increas
secret
glucagon
pancreat
cell
induc
hyperglycemia
turn
inhibit
high
glucos
environ
troglitazon
pparc
agonist
increas
express
renal
proxim
tubul
revers
downregul
express
upregul
glucagon
secret
induc
high
glucos
accordingli
pparc
antagonist
decreas
express
increas
glucagon
similar
high
glucos
ose
effect
potenti
mediat
signal
pathway
hyperglycemia
increas
akt
phosphoryl
pakt
alpha
cell
contribut
express
troglitazon
treatment
decreas
pakt
high
glucosetr
alpha
cell
addit
inhibitor
revers
high
glucoseinduc
decreas
glucagon
increas
alpha
tc
cell
glucos
transport
renal
tubular
epitheli
cell
concentr
higher
renal
interstiti
diffus
renal
interstiti
glut
basolater
membran
studi
suggest
mice
delet
present
glycosuria
human
mutat
present
fanconi
syndrom
glycosuria
proxim
tubul
dysfunct
import
biolog
function
pparc
involv
lipid
metabol
pparc
activ
fatti
acid
exogen
peroxisom
prolifer
regul
express
enzym
conduct
lipid
metabol
increas
express
pparc
found
multipl
tissu
dietinduc
obes
model
dio
pparc
induc
transcript
activ
adipocyt
gene
play
import
role
adipocyt
differenti
pparc
local
brownfatspecif
enhanc
bind
nuclear
factor
ia
nfia
brown
fat
enhanc
preced
facilit
bind
pparc
lead
increas
chromatin
access
activ
transcript
pparc
also
regul
mutual
transform
adipocyt
osteoblast
therebi
affect
lipid
metabol
promot
differenti
bone
marrow
mesenchym
stem
cell
adipocyt
inhibit
differenti
osteoblast
sever
studi
report
mutat
pparc
protein
relat
diseas
state
exampl
pparc
result
sever
obes
mutat
partial
involv
famili
lipodystrophi
type
e
kidney
one
target
organ
pparcregul
lipid
metabol
ppar
detect
rodent
human
kidney
includ
glomeruli
medullari
collect
duct
pelvic
urothelium
renal
proxim
tubul
express
lipid
metabolismrel
enzym
upregul
transcript
activ
suffici
express
pparc
kidney
process
free
fatti
acid
ffa
includ
reabsorpt
proxim
tubul
metabol
within
mitochondria
proxim
tubul
ffa
usual
metabol
method
constitut
largest
energi
pool
human
bodi
moorhead
et
al
first
report
relationship
lipid
metabol
kidney
diseas
mutat
lipid
metabol
enzym
result
lipotox
renal
function
deterior
studi
anim
model
show
pparcdefici
mice
present
lipid
metabol
disord
one
earlier
studi
use
leptin
doubl
knockout
mice
poko
show
mice
present
spontan
metabol
syndrom
hypertens
albuminuria
renal
dysfunct
anoth
studi
show
lipotox
acceler
lipid
accumul
inflamm
lead
glomerular
diseas
suggest
renal
lipid
metabol
may
serv
target
specif
therapi
aim
slow
progress
podocyt
failur
metabol
syndrom
renal
resid
macrophag
play
import
role
kidney
homeostasi
patholog
macrophag
involv
acut
kidney
diseas
chronic
kidney
diseas
adopt
differ
type
phenotyp
includ
macrophag
subtyp
macrophag
mdsc
cell
promot
kidney
injuri
cell
contribut
repair
respons
kidney
injuri
figur
kidney
delet
pparc
hematopoiet
cell
enhanc
inflammatori
renal
diseas
antigbm
antibodyinduc
glomerulonephr
mous
model
mice
lack
macrophag
express
pparc
develop
glomerulonephr
similar
autoimmun
glomerulonephr
addit
pparc
agonist
pioglitazon
decreas
renal
calcium
oxal
crystal
format
suppress
macrophag
polar
also
promot
differenti
monocyt
macrophag
delet
pparc
macrophag
lead
impair
phagocytosi
macrophag
polar
alter
lipid
handl
pparc
agonist
downregul
express
inflammatori
factor
monocyt
macrophag
inhibit
nfkappab
signal
transduc
activ
transcript
stat
pathway
pparc
agonist
block
proinflammatori
effect
ifnc
inhibit
jakstat
janu
kinasesign
transduc
activ
tranion
pathway
rat
model
type
diabet
pioglitazon
significantli
reduc
macrophag
infiltr
renal
tissu
along
inflammatori
fibrot
factor
chemokin
cc
motif
ligand
tgfb
pai
vascular
endotheli
growth
factor
vegf
addit
pparc
activ
also
modul
function
type
kidneyresid
immun
cell
cell
delet
pparc
cell
caus
loss
cell
differenti
predispos
autoimmun
diseas
hypertens
import
caus
consequ
kidney
diseas
kidney
function
alway
associ
increas
blood
pressur
bp
cric
studi
preval
hypertens
much
higher
gener
popul
hypertens
one
independ
risk
factor
progress
ckd
besid
wide
distribut
adipocyt
adren
gland
spleen
muscl
etc
pparc
also
wide
express
vascular
endotheli
cell
smooth
muscl
cell
regul
smooth
muscl
prolifer
migrat
apoptosi
inflamm
atherosclerosi
patholog
process
studi
vivo
vitro
support
pparc
play
vital
protect
role
cardiovascular
disord
studi
docasalthypertens
rat
rosiglitazon
effect
prevent
increas
blood
pressur
partial
improv
endotheli
dysfunct
recent
studi
observ
increas
express
pparc
blood
vessel
spontan
hypertens
rat
benefici
vascular
function
lower
blood
pressur
pparc
also
inhibit
growth
vascular
cell
induc
apoptosi
vascular
smooth
muscl
cell
vsmc
improv
vascular
structur
nicol
et
al
shown
abil
lower
blood
pressur
bp
endothelialspecif
pparc
activ
context
highfat
diet
mous
model
benkiran
et
al
figur
pparc
might
respons
amelior
vascular
remodel
hypertens
mechan
may
includ
inhibit
express
matrix
disturb
mapk
signal
pathway
recent
studi
report
pparc
regul
bp
reninangiotensinaldosteron
system
raa
act
neg
regul
ang
ii
receptor
transcript
via
follow
pathway
inhibit
express
angiotensinogen
inhibit
ang
ii
activ
degrad
angiotensin
receptor
express
vsmc
clinic
research
found
signific
reduct
blood
pressur
rosiglitazon
treatment
type
diabet
patient
e
data
barroso
et
al
figur
pparcdomin
neg
mutat
associ
hypertens
addit
pparc
also
import
circadian
variat
blood
pressur
heart
rate
control
cardiovascular
rhythm
via
influenc
sympathet
nerv
activ
molecular
clock
pparc
also
protect
agerel
hypertens
base
function
activ
ppar
tzd
may
becom
therapeut
agent
use
prevent
cardiovascular
diseas
beyond
effect
carbohydr
lipid
metabol
although
concern
side
effect
system
fluid
retent
propos
identifi
critic
pparc
target
gene
play
import
role
control
edema
pparc
agonist
shown
great
clinic
effect
treat
metabol
disord
mani
agonist
develop
includ
tzd
pparc
agonist
appear
use
revers
earli
stage
renal
fibrosi
epithelialmesenchym
transit
emt
condit
high
glucos
restor
function
sgltprotein
mediat
glucos
uptak
tzd
use
intern
journal
nephrolog
treatment
prove
indirectli
slow
progress
renal
diseas
improv
glucos
intoler
reduc
urinari
albumin
metaanalysi
involv
diabet
patient
demonstr
tzd
produc
signific
decreas
level
urinari
albumin
addit
ra
blockad
practic
patient
latter
studi
treat
acei
arb
accumul
evid
suggest
pparc
agonist
could
also
provid
protect
wider
spectrum
kidney
diseas
acut
nephrot
syndrom
nondiabet
glomerulosclerosi
polycyst
kidney
pioglitazon
report
improv
renal
function
anim
model
renal
ischemia
reperfusioninduc
aki
via
regul
tnf
express
furthermor
recent
studi
highlight
benefici
role
pparc
agonist
patient
chronic
renal
failur
hemodialysi
well
periton
dialysi
pd
could
also
benefit
liu
et
al
point
rosiglitazon
could
protect
high
phosphateinduc
vascular
calcif
ckd
mice
zhang
et
al
provid
evid
rosiglitazon
protect
effect
rat
periton
mesotheli
cell
pd
solutioninduc
damag
probabl
inhibit
inflamm
regul
aqp
zo
gene
express
interestingli
member
raa
inhibitor
wide
use
treatment
renal
diseas
telmisartan
character
select
pparc
modul
advantag
reduc
albuminuria
serum
creatinin
glomerulosclerosi
nondiabet
model
partial
agonist
activ
pparc
besid
treatment
telmisartan
confirm
protect
effect
daunorubicin
dnr
induc
nephrotox
reduc
level
ang
ii
express
associ
reduc
inflamm
oxid
stress
part
activ
pparc
previou
studi
shown
pparc
agonist
may
protect
effect
cvd
end
ckd
proactiv
studi
ckd
patient
treat
pioglitazon
less
like
reach
composit
end
point
allcaus
death
mi
stroke
ese
effect
may
relat
antiinflamm
effect
protect
endotheli
cell
shortterm
rosiglitazon
therapi
reduc
insulin
resist
marker
inflamm
abnorm
endotheli
function
patient
ckd
nondiabet
esrd
patient
pioglitazon
significantli
chang
visceralsubcutan
fat
distribut
improv
adipokin
profil
decreas
hepat
insulin
resist
nondiabet
renal
allograft
recipi
pioglitazon
treatment
reduc
progress
carotid
imt
improv
insulin
resist
howev
protect
effect
pparc
agonist
progress
renal
function
need
explor
despit
evid
pparc
agonist
could
obvious
bring
benefit
renal
function
state
benefici
effect
shadow
risk
fluid
retent
peripher
edema
blood
volum
expans
could
increas
variou
degre
burden
kidney
exampl
studi
prove
tzd
contribut
fluid
retent
alter
sodium
water
reabsorpt
distal
collect
duct
kidney
clinic
research
figur
uncompl
diabet
patient
combin
use
raa
inhibitor
pparc
agonist
promot
anemia
besid
peopl
longterm
tzd
drug
treatment
also
peculiarli
prone
osteoporosi
heart
failur
safeti
warn
even
drug
withdraw
europ
come
increas
risk
bladder
cancer
pioglitazon
combin
therapi
includ
pparc
agonist
renoprotect
measur
appear
reason
one
singl
intervent
ongo
effort
made
identifi
select
modul
pparc
reduc
elimin
advers
effect
pparc
agonist
overal
pparc
one
ligandactiv
transcript
factor
superfamili
member
abundantli
express
mani
type
kidney
cell
involv
renal
diseas
particip
cell
prolifer
apoptosi
pathway
inflamm
oxid
stress
lipid
metabol
hypertens
activ
pparc
improv
kidney
injuri
e
applic
clinic
treatment
restrict
side
effect
cellspecif
function
pparc
agonist
still
unclear
understand
mechan
pparc
function
explor
cell
specif
reaction
activ
pparc
agonist
develop
new
type
pparc
agonist
less
sideeffect
may
help
applic
pparc
agonist
clinic
treatment
amelior
renal
injuri
e
author
declar
conflict
interest
andliu
j
structur
draft
review
shi
wang
provid
input
liu
j
revis
final
manuscript
